Rep. Cammack Slams Drug Industry Over Soaring Prices, Consolidation, and “Buying Up the System”

WASHINGTON, D.C. —  Today, Congresswoman Kat Cammack grilled pharmaceutical and distribution executives in a Energy and Commerce Health Subcommittee hearing over exploding drug prices, industry consolidation, and a system that is squeezing working families.

“Families didn’t get a 30 percent raise,” Cammack said. “So why are they being handed 30 percent higher drug bills?”

Between 2021 and 2024, median launch prices for new drugs more than doubled. In a single year alone, more than 1,000 drugs saw price increases averaging more than 30 percent.

Cammack pressed executives on projections showing the largest distributors expect to generate $871 billion in revenue this year after years of double-digit growth. She questioned whether consolidation across manufacturing, distribution, and pharmacy operations is lowering prices or concentrating profits.

“If consolidation is delivering savings, patients should see it at the counter,” Cammack said. “Right now, they’re seeing higher bills.”

The Congresswoman also raised concerns about billions spent acquiring physician management organizations.

“When companies start buying up the business side of doctors’ offices while controlling the drug supply chain, families have every right to ask who the system is really working for,” Cammack said. “Working Americans should never feel like health care decisions are being influenced by corporate consolidation instead of patient care.”

Cammack reaffirmed her commitment to advancing reforms that increase transparency, restore competition, and deliver real relief to working families.

“This should be about patients,” Cammack said. “Not profits. Not power. Patients.”

###